Retatrutide and Heart Health: Cardiovascular Data

Introduction

Cardiovascular disease remains the leading cause of death worldwide, and obesity is one of its strongest modifiable risk factors. As a triple receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, retatrutide produces improvements across several cardiovascular risk markers, including blood pressure, triglycerides, non-HDL cholesterol, and apolipoprotein B. These changes have been documented in Phase 2 analyses and in the Phase 3 TRIUMPH-4 trial.

However, an important distinction must be made: all cardiovascular data for retatrutide to date are based on surrogate markers. No cardiovascular outcomes trial has been completed, meaning there is no direct evidence yet that retatrutide reduces heart attacks, strokes, or cardiovascular death. A dedicated outcomes trial (TRIUMPH-Outcomes) is underway but is not expected to report results until approximately 2029 or later.

Blood Pressure Reductions

Systolic Blood Pressure

Retatrutide has demonstrated clinically meaningful reductions in systolic blood pressure (SBP) across its clinical program. In the Phase 3 TRIUMPH-4 trial, participants receiving the 12 mg dose experienced a mean SBP reduction of 14.0 mmHg at 68 weeks (Eli Lilly press release, December 2025). This degree of blood pressure lowering is substantial and comparable to what might be expected from adding a dedicated antihypertensive medication.

The blood pressure effect is driven by multiple factors. Weight loss itself is a potent blood pressure intervention, with each 1% of body weight lost associated with approximately 1 mmHg reduction in systolic blood pressure. Given that TRIUMPH-4 participants at 12 mg lost an average of 28.7% of body weight, the weight-mediated contribution alone could account for a significant portion of the observed reduction.

Beyond weight loss, GLP-1 receptor agonism has direct vascular effects that may contribute additional benefit. These include promotion of natriuresis (sodium excretion by the kidneys), improved endothelial function, and reduced arterial stiffness.

Diastolic Blood Pressure

Phase 2 data showed modest reductions in diastolic blood pressure of approximately 2-4 mmHg at higher doses. While less pronounced than systolic changes, these reductions contribute to improved overall hemodynamic profile.

Clinical Significance

Blood pressure reduction is one of the most reliable predictors of cardiovascular benefit. Population-level data indicate that each 5 mmHg reduction in systolic blood pressure is associated with an approximately 10% reduction in major cardiovascular events. The 14 mmHg SBP reduction observed with retatrutide 12 mg, if confirmed in larger and longer studies, would represent a clinically important cardiovascular risk reduction based on blood pressure alone.

Lipid Profile Improvements

ESC 2024 Data

The most detailed characterization of retatrutide’s lipid effects comes from analyses presented at the European Society of Cardiology (ESC) 2024 congress, based on Phase 2 trial data at 48 weeks:

These reductions span multiple atherogenic lipid fractions and together represent a broadly favorable shift in cardiovascular lipid risk.

Non-HDL Cholesterol

Non-HDL cholesterol captures all cholesterol carried in atherogenic lipoprotein particles (VLDL, IDL, LDL, and lipoprotein(a)). It is increasingly recognized as a more comprehensive marker of atherogenic risk than LDL cholesterol alone. The 26.9% reduction observed with retatrutide is clinically meaningful and exceeds the non-HDL reductions typically reported with GLP-1 receptor agonists alone.

Triglycerides

The 40.6% triglyceride reduction is among the largest reported for any incretin-based therapy. Elevated triglycerides are independently associated with cardiovascular risk and are a hallmark of the metabolic dyslipidemia seen in obesity and insulin resistance. This magnitude of reduction approaches what can be achieved with dedicated triglyceride-lowering therapies such as high-dose omega-3 fatty acids or fibrates.

Apolipoprotein B

ApoB is present on every atherogenic lipoprotein particle and is considered by some cardiologists to be the single best marker of atherogenic particle burden. The 24.2% reduction in ApoB suggests that retatrutide reduces the total number of atherogenic particles, not just the cholesterol content within them.

Apolipoprotein C-III

ApoC-III is an emerging cardiovascular risk marker that inhibits lipoprotein lipase and promotes triglyceride-rich lipoprotein accumulation. The 38.0% reduction in ApoC-III is notable because elevated ApoC-III has been associated with increased cardiovascular events in genetic and epidemiological studies. This reduction may reflect a mechanistic pathway related to glucagon receptor activation.

The ANGPTL3/8 Mechanism

Research published by Wen et al. (2025) in Diabetes, Obesity and Metabolism has elucidated a potential mechanism for retatrutide’s lipid-lowering effects beyond weight loss. Glucagon receptor activation appears to reduce hepatic secretion of angiopoietin-like proteins 3 and 8 (ANGPTL3 and ANGPTL8). These proteins normally inhibit lipoprotein lipase, the enzyme responsible for clearing triglyceride-rich lipoproteins from the bloodstream.

By reducing ANGPTL3/8 levels, glucagon receptor agonism may enhance triglyceride clearance independently of weight loss. This mechanism could explain why retatrutide produces larger triglyceride reductions than might be expected from its weight loss alone and distinguishes its lipid effects from those of GLP-1-selective or GIP/GLP-1 dual agonists that lack a glucagon receptor component.

Heart Rate Considerations

GLP-1 receptor agonists as a class are associated with modest increases in resting heart rate, typically in the range of 2-4 beats per minute. This effect has been observed across all approved GLP-1 receptor agonists, including semaglutide and tirzepatide.

As a GLP-1 receptor agonist, retatrutide would be expected to produce a similar heart rate increase. Phase 2 data are consistent with this class effect. Heart rate increases of approximately 5-10 bpm have been reported in the clinical program.

The clinical significance of this heart rate increase has been debated. In the semaglutide SELECT trial, a net cardiovascular benefit was demonstrated despite the heart rate increase, suggesting that any adverse effect of modest heart rate elevation is more than offset by other cardiovascular benefits. However, for individual patients with pre-existing tachyarrhythmias or heart rate-sensitive conditions, this effect warrants clinical consideration.

Cardiovascular Outcomes: What We Know and Do Not Know

No Outcomes Data Yet

It is essential to understand that retatrutide does not yet have cardiovascular outcomes data. All of the data described above are surrogate markers, which are measurements that correlate with cardiovascular risk but do not directly demonstrate that events (heart attacks, strokes, cardiovascular death) are reduced.

History has shown that surrogate marker improvements do not always translate into outcomes benefit. Some interventions that improved lipid profiles or blood pressure failed to reduce cardiovascular events in dedicated outcomes trials. Conversely, some therapies produced cardiovascular benefits beyond what surrogate markers predicted.

TRIUMPH-Outcomes Trial

Eli Lilly has initiated TRIUMPH-Outcomes (NCT06383390), a large, event-driven cardiovascular and kidney outcomes trial in patients with obesity and established atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease (CKD). This trial is designed to determine whether retatrutide reduces major adverse cardiovascular events (MACE) and kidney outcomes.

Because it is event-driven, the trial duration depends on how many cardiovascular events accumulate among participants. Based on typical timelines for such trials, results are not expected until approximately 2029 or later. Until these data are available, the cardiovascular effects of retatrutide remain promising but unproven at the outcomes level.

Context: The Semaglutide SELECT Trial

The semaglutide SELECT trial (2023) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with overweight or obesity and established cardiovascular disease, without diabetes. This was the first cardiovascular outcomes trial to demonstrate that a GLP-1 receptor agonist reduces cardiovascular events in a non-diabetic population, and it established an important precedent for the incretin class.

Whether retatrutide’s triple receptor mechanism translates into similar, greater, or lesser cardiovascular benefit than semaglutide remains unknown. The additional GIP and glucagon receptor agonism could provide incremental benefit through enhanced lipid lowering and metabolic improvement, but this is speculative until outcomes data are available.

Context: The Tirzepatide SURPASS-CVOT

Tirzepatide (Zepbound/Mounjaro), a dual GIP/GLP-1 receptor agonist also developed by Eli Lilly, is being evaluated in its own cardiovascular outcomes trial (SURPASS-CVOT). Results from this trial will provide further insight into whether adding GIP receptor agonism to GLP-1 agonism enhances cardiovascular outcomes beyond what GLP-1 alone achieves. These data will be relevant context for interpreting eventual retatrutide outcomes.

Other Cardiovascular Markers

hsCRP (Inflammation)

The TRIUMPH-4 trial reported reductions in high-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation. Chronic low-grade inflammation is recognized as a contributor to atherosclerotic cardiovascular disease, and its reduction is associated with lower cardiovascular event rates. However, the magnitude and consistency of hsCRP reduction across retatrutide studies has not been fully characterized in published data.

Waist Circumference

Visceral adiposity, reflected by waist circumference, is an independent cardiovascular risk factor. Retatrutide produces substantial reductions in waist circumference (approximately 10-15 cm at higher doses in Phase 2), consistent with preferential visceral fat loss. Visceral fat reduction is associated with improved insulin sensitivity, lower inflammation, and reduced cardiovascular risk beyond what total weight loss alone would predict.

Summary

Retatrutide produces improvements across a broad range of cardiovascular surrogate markers, including clinically meaningful blood pressure reduction (-14 mmHg SBP at 12 mg), substantial lipid improvements (non-HDL-C -26.9%, triglycerides -40.6%, ApoB -24.2%, ApoC-III -38.0%), and reductions in inflammatory markers. The glucagon receptor component may provide lipid-lowering benefits beyond what GLP-1 agonism alone achieves, potentially through ANGPTL3/8 suppression.

However, these remain surrogate markers only. Cardiovascular outcomes data from the TRIUMPH-Outcomes trial are needed to determine whether retatrutide reduces cardiovascular events. Until then, the cardiovascular profile is encouraging but unproven at the clinical outcomes level.

Frequently Asked Questions

Does retatrutide lower blood pressure?

Yes. In the Phase 3 TRIUMPH-4 trial, retatrutide 12 mg reduced systolic blood pressure by an average of 14.0 mmHg at 68 weeks (Eli Lilly press release, December 2025). This reduction is driven by substantial weight loss and potentially by direct vascular effects of GLP-1 receptor agonism, including natriuresis and improved endothelial function.

Does retatrutide lower cholesterol?

Retatrutide reduces non-HDL cholesterol by approximately 26.9% and apolipoprotein B (ApoB) by approximately 24.2% at 48 weeks, based on Phase 2 data presented at ESC 2024. LDL cholesterol changes have been more modest and variable. For patients requiring significant LDL lowering, statin therapy remains the standard of care and would typically be used alongside retatrutide rather than replaced by it.

Does retatrutide reduce the risk of heart attack or stroke?

There is no direct evidence yet that retatrutide reduces cardiovascular events such as heart attacks or strokes. All cardiovascular data to date are surrogate markers (blood pressure, lipids, inflammatory markers). The TRIUMPH-Outcomes trial is underway to answer this question, but results are not expected until approximately 2029 or later.

Does retatrutide increase heart rate?

GLP-1 receptor agonists as a class produce modest increases in resting heart rate, typically 2-4 bpm. Retatrutide appears to follow this pattern, with reported heart rate increases in the range of 5-10 bpm. The semaglutide SELECT trial demonstrated net cardiovascular benefit despite this class effect, but heart rate should be monitored in patients with relevant pre-existing conditions.

How does retatrutide compare to semaglutide for cardiovascular health?

Semaglutide has proven cardiovascular outcomes benefit from the SELECT trial (20% reduction in MACE). Retatrutide has stronger surrogate marker improvements (greater weight loss, larger lipid reductions) but no outcomes data yet. It is not possible to determine whether retatrutide is superior, equivalent, or inferior to semaglutide for cardiovascular outcomes until the TRIUMPH-Outcomes trial reports results.

What is the TRIUMPH-Outcomes trial?

TRIUMPH-Outcomes (NCT06383390) is a large, event-driven Phase 3 trial evaluating whether retatrutide reduces major adverse cardiovascular events and kidney outcomes in patients with obesity and established atherosclerotic cardiovascular disease or chronic kidney disease. It is currently recruiting, and results are expected approximately 2029 or later given the event-driven design.